39 results on '"Garbes P"'
Search Results
2. GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults
- Author
-
Christine D. Palmer, Ciaran D. Scallan, Lauren D. Kraemer Tardif, Melissa A. Kachura, Amy R. Rappaport, Daniel O. Koralek, Alison Uriel, Leonid Gitlin, Joshua Klein, Matthew J. Davis, Harshni Venkatraman, Meghan G. Hart, Jason R. Jaroslavsky, Sonia Kounlavouth, Martina Marrali, Charmaine N. Nganje, Kyounghwa Bae, Tiffany Yan, Katharyn Leodones, Milana Egorova, Sue-Jean Hong, Jenchun Kuan, Silvia Grappi, Pedro Garbes, Karin Jooss, and Andrew Ustianowski
- Subjects
Science - Abstract
Abstract SARS-CoV-2 has resulted in high levels of morbidity and mortality world-wide, and severe complications can occur in older populations. Humoral immunity induced by authorized vaccines wanes within 6 months, and frequent boosts may only offer transient protection. GRT-R910 is an investigational self-amplifying mRNA (samRNA)-based SARS-CoV-2 vaccine delivering full-length Spike and selected conserved non-Spike T cell epitopes. This study reports interim analyses for a phase I open-label dose-escalation trial evaluating GRT-R910 in previously vaccinated healthy older adults (NCT05148962). Primary endpoints of safety and tolerability were assessed. Most solicited local and systemic adverse events (AEs) following GRT-R910 dosing were mild to moderate and transient, and no treatment-related serious AEs were observed. The secondary endpoint of immunogenicity was assessed via IgG binding assays, neutralization assays, interferon-gamma ELISpot, and intracellular cytokine staining. Neutralizing antibody titers against ancestral Spike and variants of concern were boosted or induced by GRT-R910 and, contrasting to authorized vaccines, persisted through at least 6 months after the booster dose. GRT-R910 increased and/or broadened functional Spike-specific T cell responses and primed functional T cell responses to conserved non-Spike epitopes. This study is limited due to small sample size, and additional data from ongoing studies will be required to corroborate these interim findings.
- Published
- 2023
- Full Text
- View/download PDF
3. Linking proteomic alterations in schizophrenia hippocampus to NMDAr hypofunction in human neurons and oligodendrocytes
- Author
-
Zuccoli, Giuliana S., Reis-de-Oliveira, Guilherme, Garbes, Bruna, Falkai, Peter, Schmitt, Andrea, Nakaya, Helder I., and Martins-de-Souza, Daniel
- Published
- 2021
- Full Text
- View/download PDF
4. Ionic effects on the electric field needed to orient dielectric lamellae
- Author
-
Putzel, Gregory Garbès, Andelman, David, Tsori, Yoav, and Schick, Michael
- Subjects
Condensed Matter - Soft Condensed Matter - Abstract
We consider the effect of mobile ions on the applied potential needed to reorient a lamellar system of two different materials placed between two planar electrodes. The reorientation occurs from a configuration parallel to the electrodes favored by surface interactions to an orientation perpendicular to the electrodes favored by the electric field. The system consists of alternating A and B layers with different dielectric constants. The mobile ions are assumed to be insoluble in the B layers and hence confined to the A layers. We find that the ions reduce the needed voltage most strongly when they are constrained such that each A lamella is electrically neutral. In this case, a macroscopic separation of charge and its concomitant lowering of free energy, is attained only in the perpendicular orientation. When the ions are free to move between different A layers, such that charge neutrality is only required globally, their effect is smaller and depends upon the preferred surface interaction of the two materials. Under some conditions, the addition of ions can actually stabilize the parallel configuration. Our predictions are relevant to recent experiments conducted on lamellar phases of diblock copolymer films with ionic selective impurities., Comment: To be published in the Journal of Chemical Physics
- Published
- 2010
- Full Text
- View/download PDF
5. Phenomenological Model and Phase Behavior of Saturated and Unsaturated Lipids and Cholesterol
- Author
-
Putzel, Gregory Garbès and Schick, Michael
- Subjects
Physics - Biological Physics - Abstract
We present a phenomenological theory for the phase behavior of ternary mixtures of cholesterol and saturated and unsaturated lipids, one which describes both liquid and gel phases, and illuminates the mechanism of the behavior. In a binary system of the lipids, the two phase separate when the saturated chains are well ordered, as in the gel phase, simply due to packing effects. In the liquid phase the saturated ones are not sufficiently well ordered for separation to occur. The addition of cholesterol, however, increases the saturated lipid order to the point that phase separation is once again favorable. For the system above the main chain transition of the saturated lipid, we can obtain phase diagrams in which there is liquid-liquid phase separation in the ternary system but not in any of the binary ones, while below that temperature we obtain the more common phase diagram in which a gel phase, rich in saturated lipid, appears in addition to the two liquid phases., Comment: 16 pages, 2 figures
- Published
- 2008
6. A randomized controlled trial to evaluate performance of pigs raised in antibiotic-free or conventional production systems following challenge with porcine reproductive and respiratory syndrome virus.
- Author
-
Scott Dee, Jose Ezequiel Guzman, Dan Hanson, Noel Garbes, Robert Morrison, Deborah Amodie, and Lucina Galina Pantoja
- Subjects
Medicine ,Science - Abstract
The trial objective was to compare the performance and animal health parameters of pigs raised according to one of 3 antibiotic (AB) protocols: standard AB medication consisting of mass treatment on days 4 and 21 and judicious AB therapy given therapeutically thereafter as group medication in water and feed or by individual injection (group T1, N = 702); modified AB medication identical to group T1 but with mass treatment only on day 4 and without subsequent therapeutic feed medication (group T2, N = 675); or an antibiotic-free (ABF) regimen (group T3, N = 702). All pigs were vaccinated with a modified-live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine 3 days after weaning. Using a seeder pig model to mimic endemic field infection dynamics, pigs were contact-challenged with virulent PRRSV lineage 1 strain 174 four weeks after vaccination. At finishing, average daily gain (ADG) and mean feed conversion ratio (FCR) were significantly better (p ≤ 0.05) for the T1 and T2 groups compared to the T3 group. There were no significant differences in post-weaning ADG and FCR between the T1 and T2 groups. Mortality and removals significantly favored (p ≤0.05) the T1 and T2 groups (20.94% and 24.89%, respectively) versus the T3 group (57.98%). Net revenue per pig was $105.43, $98.79, and $33.81 for the T1, T2 and T3 groups, respectively. Under the conditions of this study, these results indicate that in a PRRSV-endemic setting involving bacterial co-infections, an ABF production strategy may leave pigs at considerable risk of exposure to severe clinical disease and that judicious use of antibiotics can significantly improve animal health.
- Published
- 2018
- Full Text
- View/download PDF
7. Beliefs, Attitudes, and Propensity To Buy Locally Produced Food
- Author
-
Steven Dukeshire, Renée Garbes, Chloe Kennedy, Ainslie Boudreau, and Theresa Osborne
- Subjects
Agricultural Fairs ,Buy Local ,Consumer Attitudes ,Farmers' Markets ,Local Food ,Nova Scotia ,Agriculture ,Human settlements. Communities ,HT51-65 - Abstract
In this study, conducted in Nova Scotia, Canada, we surveyed people at farmers' markets, agricultural fairs, and other agricultural events to investigate the views of people who would likely be trying to incorporate local food into their everyday shopping habits. Survey respondents (N = 2,316) indicated strong positive beliefs, attitudes, and propensity toward buying local food. At the same time, however, they reported difficulty identifying whether food was local as well as a lack of opportunities to buy local food. The findings build upon the growing body of research surrounding the "buy local" movement in North America by providing insight into why people want to buy local and potential barriers that prevent stronger markets for local food products.
- Published
- 2016
- Full Text
- View/download PDF
8. Desafios na profilaxia do tromboembolismo venoso: abordagem do paciente crítico Challenges in prevention venous thromboembolism: critical ill patient approach
- Author
-
Marcelo Andrade Ribeiro, Pedro Garbes Netto, and Silvia Gelas Lage
- Subjects
paciente crítico ,prevenção de TVP ,trombose venosa profunda ,tromboembolismo pulmonar ,deep vein thrombosis ,ICU patients ,pulmonary embolism ,VTE prevention ,Medical emergencies. Critical care. Intensive care. First aid ,RC86-88.9 - Abstract
JUSTIFICATIVA E OBJETIVOS: O tromboembolismo venoso (TEV), que inclui a trombose venosa profunda (TVP) e o tromboembolismo pulmonar (TEP) são complicações comuns em pacientes críticos. A ocorrência de TEV acarreta um substancial aumento da morbimortalidade dos pacientes internados em unidades de terapia intensiva (UTI). CONTEÚDO: A maioria dos pacientes críticos apresenta alto risco para ocorrência de complicações tromboembólicas, entretanto, a prevenção do TEV muitas vezes não é realizada de maneira adequada para este grupo de pacientes. A heparina de baixo peso molecular (HBPM) parece ser o método mais eficiente para a prevenção do TEV em pacientes de UTI. Entretanto, é patente a escassez de estudos voltados para esta população, cujas particularidades levam a recomendações específicas em relação ao diagnóstico e tratamento. CONCLUSÕES: Esta revisão faz uma análise do risco, discute os principais trabalhos publicados a respeito da profilaxia e sugere estratégias para a diminuição da ocorrência de TEV nos pacientes críticos.BACKGROUND AND OBJECTIVES: Venous thromboembolism (VTE), with includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common complication in critically ill patients, resulting in high morbidity and mortality. CONTENTS: Most patients treated in intensive care units (ICU) face a high risk of thromboembolic complications. Despite these considerations, the prevention of VTE may not be as high a priority in ICU patients as it is in other high-risk patient groups. Low molecular weight heparin (LMWH) may be the optimal prophylaxis in most ICU patients, but there is a lack of sufficient data including the paucity of VTE consensus and guidelines documents pertaining to critically ill patients. CONCLUSIONS: This article reviews background, current options, and recommendations regarding VTE in intensive care population emphasizing special diagnostic and treatment considerations in the ICU setting.
- Published
- 2006
- Full Text
- View/download PDF
9. Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
- Author
-
Montgomery, Hugh, Hobbs, F D Richard, Padilla, Francisco, Arbetter, Douglas, Templeton, Alison, Seegobin, Seth, Kim, Kenneth, Campos, Jesus Abraham Simón, Arends, Rosalinda H, Brodek, Bryan H, Brooks, Dennis, Garbes, Pedro, Jimenez, Julieta, Koh, Gavin C K W, Padilla, Kelly W, Streicher, Katie, Viani, Rolando M, Alagappan, Vijay, Pangalos, Menelas N, and Esser, Mark T
- Subjects
COVID-19 treatment ,COVID-19 ,INTRAMUSCULAR injections ,ANTIGEN analysis ,COVID-19 vaccines - Abstract
Early intramuscular administration of SARS-CoV-2-neutralising monoclonal antibody combination, tixagevimab–cilgavimab, to non-hospitalised adults with mild to moderate COVID-19 has potential to prevent disease progression. We aimed to evaluate the safety and efficacy of tixagevimab–cilgavimab in preventing progression to severe COVID-19 or death. TACKLE is an ongoing, phase 3, randomised, double-blind, placebo-controlled study conducted at 95 sites in the USA, Latin America, Europe, and Japan. Eligible participants were non-hospitalised adults aged 18 years or older with a laboratory-confirmed SARS-CoV-2 infection (determined by RT-PCR or an antigen test) from any respiratory tract specimen collected 3 days or less before enrolment and who had not received a COVID-19 vaccination. A WHO Clinical Progression Scale score from more than 1 to less than 4 was required for inclusion and participants had to receive the study drug 7 days or less from self-reported onset of mild to moderate COVID-19 symptoms or measured fever. Participants were randomly assigned (1:1) to receive either a single tixagevimab–cilgavimab 600 mg dose (two consecutive 3 mL intramuscular injections, one each of 300 mg tixagevimab and 300 mg cilgavimab) or placebo. Randomisation was stratified (using central blocked randomisation with randomly varying block sizes) by time from symptom onset, and high-risk versus low-risk of progression to severe COVID-19. Participants, investigators, and sponsor staff involved in the treatment or clinical evaluation and monitoring of the participants were masked to treatment-group assignments. The primary endpoints were severe COVID-19 or death from any cause through to day 29, and safety. This study is registered with ClinicalTrials.gov , NCT04723394. Between Jan 28, 2021, and July 22, 2021, 1014 participants were enrolled, of whom 910 were randomly assigned to a treatment group (456 to receive tixagevimab–cilgavimab and 454 to receive placebo). The mean age of participants was 46·1 years (SD 15·2). Severe COVID-19 or death occurred in 18 (4%) of 407 participants in the tixagevimab–cilgavimab group versus 37 (9%) of 415 participants in the placebo group (relative risk reduction 50·5% [95% CI 14·6–71·3]; p=0·0096). The absolute risk reduction was 4·5% (95% CI 1·1–8·0; p<0·0001). Adverse events occurred in 132 (29%) of 452 participants in the tixagevimab–cilgavimab group and 163 (36%) of 451 participants in the placebo group, and were mostly of mild or moderate severity. There were three COVID-19-reported deaths in the tixagevimab–cilgavimab group and six in the placebo group. A single intramuscular tixagevimab–cilgavimab dose provided statistically and clinically significant protection against progression to severe COVID-19 or death versus placebo in unvaccinated individuals and safety was favourable. Treating mild to moderate COVID-19 earlier in the disease course with tixagevimab–cilgavimab might lead to more favourable outcomes. AstraZeneca. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Love IS AN Action Verb.
- Author
-
GARBES, ANGELA
- Subjects
VERBS ,EARWAX ,SOCIAL norms ,EAR canal ,SEXUAL excitement - Abstract
With careful, callused fingers she takes the silver pantutule and swirls it around the outer edges of my ear, then works her way in deep, scooping out my soft, crumbly white ear wax. Cleaning my ears right after a bath made it easier - body damp and relaxed, ear wax softened. Listening to Women: New Voices, New Solutions My mother sits in a green vinyl chair next to a blue-and-white faux marble counter scattered with jewelry and glass bottles. [Extracted from the article]
- Published
- 2022
11. Nonsense-mediated messenger RNA decay of survival motor neuron 1 causes spinal muscular atrophy
- Author
-
Brichta, Lars, Garbes, Lutz, Jedrzejowska, Maria, Grellscheid, Sushma-Nagaraja, Holker, Irmgard, Zimmermann, Katharina, and Wirth, Brunhilde
- Published
- 2008
- Full Text
- View/download PDF
12. Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
- Author
-
Ginde, Adit A., Paredes, Roger, Murray, Thomas A., Engen, Nicole, Grandits, Greg, Vekstein, Andrew, Ivey, Noel, Mourad, Ahmad, Sandkovsky, Uriel, Gottlieb, Robert L., Berhe, Mezgebe, Jain, Mamta K., Marines-Price, Rubria, Agbor Agbor, Barbine Tchamba, Mateu, Lourdes, España-Cueto, Sergio, Lladós, Gemma, Mylonakis, Eleftherios, Rogers, Ralph, Shehadeh, Fadi, Filbin, Michael R., Hibbert, Kathryn A., Kim, Kami, Tran, Thanh, Morris, Peter E., Cassity, Evan P., Trautner, Barbara, Pandit, Lavannya M., Knowlton, Kirk U., Leither, Lindsay, Matthay, Michael A., Rogers, Angela J., Drake, Wonder, Jones, Beatrice, Poulakou, Garyfallia, Syrigos, Konstantinos N., Fernández-Cruz, Eduardo, Natale, Marisa Di, Almasri, Eyad, Balerdi-Sarasola, Leire, Bhagani, Sanjay R., Boyle, Katherine L., Casey, Jonathan D., Chen, Peter, Douin, David J., Files, D. Clark, Günthard, Huldrych F., Hite, R. Duncan, Hyzy, Robert C., Khan, Akram, Kibirige, Moses, Kidega, Robert, Kiweewa, Francis, Jensen, Jens-Ulrik, Leshnower, Bradley G., Lutaakome, Joseph K., Manian, Prasad, Menon, Vidya, Morales-Rull, Jose Luis, O'Mahony, D. Shane, Overcash, J. Scott, Ramachandruni, Srikant, Steingrub, Jay S., Taha, Hassan S., Waters, Michael, Young, Barnaby E., Phillips, Andrew N., Murray, Daniel D., Jensen, Tomas O., Padilla, Maria L., Sahner, David, Shaw-Saliba, Katy, Dewar, Robin L., Teitelbaum, Marc, Natarajan, Ven, Rehman, M. Tauseef, Pett, Sarah, Hudson, Fleur, Touloumi, Giota, Brown, Samuel M., Self, Wesley H., Chang, Christina C., Sánchez, Adriana, Weintrob, Amy C., Hatlen, Timothy, Grund, Birgit, Sharma, Shweta, Reilly, Cavan S., Garbes, Pedro, Esser, Mark T., Templeton, Alison, Babiker, Abdel G., Davey, Victoria J., Gelijns, Annetine C., Higgs, Elizabeth S., Kan, Virginia, Matthews, Gail, Thompson, B. Taylor, Neaton, James D., Lane, H. Clifford, and Lundgren, Jens D.
- Abstract
Tixagevimab–cilgavimab is a neutralising monoclonal antibody combination hypothesised to improve outcomes for patients hospitalised with COVID-19. We aimed to compare tixagevimab–cilgavimab versus placebo, in patients receiving remdesivir and other standard care.
- Published
- 2022
- Full Text
- View/download PDF
13. Resistance patterns of S. pneumoniae and H. influenzae isolated from children with upper respiratory tract infection in Southern Brazil - 2003 and 2004: P1358
- Author
-
Mendes, C. M., Arruda, A. C., Oplustil, C., Sampaio, J. L., Garbes, P., Lima, P., Pedneault, L., Gonçalves, A., Dias, C., Barth, A., and Kiffer, C. R.
- Published
- 2005
14. Use of spatial analysis on a survey of H. influenzae and S. pneumoniae isolated from children in an urban area of southeastern Brazil: P1284
- Author
-
Monteiro, A. M., Mendes, C. M., Sampaio, J. L., Oplustil, C., Garbes, P., Lima, P., Pedneault, L., Camara, G., and Kiffer, C. R.
- Published
- 2005
15. Correlation of S. pneumoniae and H. influenzae antimicrobial resistance and history of antimicrobial use or vaccination in children with upper respiratory tract infections – Brazil 2002 to 2004: P1238
- Author
-
Mendes, C. M., Oplustil, C., Sampaio, J. L., Garbes, P., Lima, P., Pedneault, L., and Kiffer, C. R.
- Published
- 2005
16. Resistance profile of S. pneumoniae and beta-lactamase production in H. influenzae and M. catarrhalis isolated from 258 children with upper respiratory tract infection in Southern Brazil – 2002
- Author
-
Mendes, C., Zoccoli, C., Rossi, F., Duboc, G., Garbes, P., Pedneault, L., Sampaio, J., and Kiffer, C.
- Published
- 2004
17. Sobre a Transmissão Sexual do Vírus da Hepatite C (HCV)
- Author
-
Ivan Márcio Stabnov and Pedro Garbes-Netto
- Subjects
Hepatite C ,epidemiologia ,transmissão sexual ,Medicine - Abstract
Apresenta-se um estudo retrospectivo bibligráfico sobre a transmissão sexual do HCV, listando as principais evidências que indicam a sua ocorrência e os principais pontos que não a favorecem. É feita uma revisão sobre a sua etiologia e epidemiologia, ressaltando-se a importância da via sexual na manutenção do HCV na natureza, principalmente em contextos de alta endemicidade e métodos de prevenção.
- Published
- 1995
18. Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial
- Author
-
Biswal, Shibadas, Borja-Tabora, Charissa, Martinez Vargas, Luis, Velásquez, Hector, Theresa Alera, Maria, Sierra, Victor, Johana Rodriguez-Arenales, Edith, Yu, Delia, Wickramasinghe, V Pujitha, Duarte Moreira, Edson, Fernando, Asvini D, Gunasekera, Dulanie, Kosalaraksa, Pope, Espinoza, Felix, López-Medina, Eduardo, Bravo, Lulu, Tuboi, Suely, Hutagalung, Yanee, Garbes, Pedro, Escudero, Ian, Rauscher, Martina, Bizjajeva, Svetlana, LeFevre, Inge, Borkowski, Astrid, Saez-Llorens, Xavier, Wallace, Derek, Concepción, Alys, Villarreal, Ana Cecilia, Fernando, Asvini, Borja-Tabora, Charissa, Sirivichayakul, Chukiat, Yu, Delia, Gunasekera, Dulanie, López-Medina, Eduardo, Rodriguez-Arenales, Edith Johanna, Moreira, Edson Duarte, Espinoza, Felix, Velásquez, Hector, Reynales, Humberto, Luz, Kleber, Jimeno, Jose, Fernando, LakKumar, Bravo, Lulu, Vargas, Luis Martinez, Rivera, Luis, Alera, Maria Theresa, Manacharoen, Onanong, Lopez, Pio, Kosalaraksa, Pope, Wickramasinghe, V. Pujitha, Dietze, Reynaldo, da Cunha, Rivaldo Venâncio, Watanaveeradej, Veerachai, Sierra, Victor, Saez-Llorens, Xavier, Biswal, Shibadas, Brose, Manja, Rauscher, Martina, Bizjajeva, Svetlana, LeFevre, Inge, Borkowski, Astrid, Wallace, Derek, Escudero, Ian, Moss, Kelley, Garbes, Pedro, Meyer, Seetha, Hutagalung, Yanee, Tuboi, Suely, and Tricou, Vianney
- Abstract
A substantial unmet need remains for safe and effective vaccines against dengue virus disease, particularly for individuals who are dengue-naive and those younger than 9 years. We aimed to assess the efficacy, safety, and immunogenicity of a live attenuated tetravalent dengue vaccine (TAK-003) in healthy children aged 4–16 years.
- Published
- 2020
- Full Text
- View/download PDF
19. Sound Archive Access: Revealing Emergent Cultures.
- Author
-
Garbes, Laura
- Subjects
SOUND archives ,PRESSURE groups ,HISTORY of radio broadcasting ,CULTURAL appropriation ,SCHOLARS - Abstract
This article contends that researchers can and should be active participants in making sound archives more accessible. In fact, such advocacy can be consequential in setting up possibilities for creative research on race within radio history and sound studies. Using the example of NPR's All Things Considered archive spanning from 1971–1983, I demonstrate how academics and archivists can work together to make possible the preservation and accessibility of sound archives. This particular collaboration offers an opportunity to take a cultural approach to understanding newsroom diversity, more specifically: the cultural constraints of linguistic norms and the emergent cultures that arise as aberrations from such norms. The article reflects on this project's implications for other scholars who work with archives that wish to invest in sound archive preservation and use. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. AIDS Sarcoma de Kaposi epidêmico
- Author
-
Sérgio Setúbal, Roberto Zajdenverg, and Pedro Garbes Netto
- Subjects
Medicine - Abstract
O sarcoma de Kaposi, até há alguns anos um tumor raro, adquiriu importância pela sua associação com a síndrome de imunodeficiência adquirida (SIDA). [...]
- Published
- 1989
21. Boy or Girl: Does Gender Matter When Learning to Farm Safely?
- Author
-
Dukeshire, S. R., Sanderson, L. L., Garbes, R., and Wang, X.
- Subjects
FARM management research ,CHILD agricultural laborers ,HEALTH of agricultural laborers - Abstract
Based on a survey and face-to-face interview with 24 students who lived most of their lives on farms, this study extends the findings of previously reported research by examining similarities and differences between males' and females' beliefs, attitudes, and adoption offarm health and safety practices. The survey and interview asked participants to recall their experiences growing up on a farm and in particular how they learned tofarm safely. Data were analyzed qualitatively, focusing on two potentially gendered farm chores: tractor operation and livestock handling. Particular emphasis was placed on identifying similarities and differences between boys' and girls' childhood farm experiences and transfer of farm health and safety knowledge. Main findings indicated that although there may be some differences between how boys and girls perceive the operational aspects of the farm (particularly parental roles), there seems to be little difference between genders in terms of tasks they were permitted to do and in their health and safely practices. The current study adds to a small but growing literature suggesting that gender differences play a relatively small role in farm health and safety practices among individuals strongly committed to and engaged in agriculture. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
22. Prospective Cohort Study with Active Surveillance for Fever in Four Dengue Endemic Countries in Latin America.
- Author
-
Dayan, Gustavo, Arredondo, Jose L., Carrasquilla, Gabriel, Deseda, Carmen C., Dietze, Reynaldo, Luz, Kleber, Costa, Maria Selma N., Cunha, Rivaldo V., Rey, Luis C., Morales, Javier, Reynales, Humberto, Miranda, Maria, Zambrano, Betzana, Rivas, Enrique, Garbes, Pedro, and Noriega, Fernando
- Published
- 2015
- Full Text
- View/download PDF
23. Immunogenicity and Safety of a Recombinant Tetravalent Dengue Vaccine in Children and Adolescents Ages 9-16 Years in Brazil.
- Author
-
Dayan, Gustavo H., Garbes, Pedro, Noriega, Fernando, de Sadovsky, Ana Daniela Izoton, Rodrigues, Patricia Marques, Giuberti, Camila, and Dietze, Reynaldo
- Published
- 2013
- Full Text
- View/download PDF
24. Evaluating human neural tuning curves from a mechanical model of the cochlea by relating them to psychophysical masking data
- Author
-
Garbes, P. A., primary and Allen, J. B., additional
- Published
- 1995
- Full Text
- View/download PDF
25. Deriving human neural tuning curves from a mechanical model of the cochlea
- Author
-
Garbes, P. A., primary and Allen, J. B., additional
- Published
- 1994
- Full Text
- View/download PDF
26. Challenges in the clinical development of a dengue vaccine.
- Author
-
Wallace, Derek, Canouet, Vincent, Garbes, Pedro, and Wartel, T Anh
- Abstract
Highlights: [•] Dengue is the fastest spreading vector borne viral disease. [•] A vaccine would provide an important public health tool. [•] Vaccine candidates must demonstrate safety and efficacy in clinical trials. [•] Study sites must ensure high quality, long term surveillance. [•] Appropriate preparation and community engagement are critical. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
27. Molecular cloning and characterization of N-syndecan, a novel transmembrane heparan sulfate proteoglycan
- Author
-
Carey, DJ, primary, Evans, DM, additional, Stahl, RC, additional, Asundi, VK, additional, Conner, KJ, additional, Garbes, P, additional, and Cizmeci-Smith, G, additional
- Published
- 1992
- Full Text
- View/download PDF
28. The Farm Apprentice: Agricultural College Students Recollections of Learning to Farm "Safely".
- Author
-
Sanderson, L. L., Dukeshire, S. R., Rangel, C., and Garbes, R.
- Subjects
AGRICULTURAL students ,AGRICULTURE ,APPRENTICESHIP programs ,FARMERS ,CONDUCT of life - Abstract
The article presents a study which evaluates the influence of apprentice farming on safety beliefs, attitudes, and farming practices of 24 farm youth attending the Nova Scotia Agricultural College. The study is conducted through semi-structured interviews designed to derive information regarding the respondents' memories of their involvement in farming. The results showed that early experience related to farming appears to be an integral part of the social context of the farming community.
- Published
- 2010
- Full Text
- View/download PDF
29. To the Bards: The Choral Works of Estonian Composer Ester Mägi.
- Author
-
Garbes, Heather Maclaughlin
- Abstract
An essay is presented on the life and works of composer Ester Mägi. It discusses the contributions of Mägi to the Estonian choral music, her Estonian national music style, and the awards and titles she received. It mentions the genres which she composed except for stage music and her compositional techniques by focusing on folk melodies harmonized in romantic style like her pice "Leidsid sõnad kalli viisi (Leaves Falling) and keeping her compositions fresh and modern.
- Published
- 2009
30. Histone Acetylation as a Potential Therapeutic Target in Motor Neuron Degenerative Diseases
- Author
-
Garbes, Lutz, Riessland, Markus, and Wirth, Brunhilde
- Abstract
Among hereditary diseases, the group of motor neuron diseases (MNDs) includes some of the most devastating and rapidly progressive lethal conditions. Although degeneration of motor neurons is common to all of them, the phenotypic spectrum of MNDs is relatively broad and ranges from perinatal conditions like spinal muscular atrophy (SMA) to adult-onset diseases such as amyotrophic lateral sclerosis (ALS). While the understanding of the pathology of the diseases is constantly growing, the development of therapeutic approaches lags behind. In fact, there is no approved therapy for MNDs available at the moment. Recent findings demonstrated the existence of some patterns that are shared by several MNDs such as transcriptional dysregulation. In addition, conditions like SMA or certain types of Charcot-Marie-Tooth disease provide some defined targets which may be amenable to therapeutic approaches. Consequently, counteracting this dysregulation may be a valuable therapeutic option and ameliorate disease progression in MND patients. The feasibility of such an approach has been proven during the past years by the epigenetic treatment of various neoplastic entities with histone deacetylase inhibitors (HDACi). On these grounds, also epigenetic therapy of MNDs has become a promising option. So far, several HDACi have been tested in vitro and in animal models and some proceeded further and were evaluated in clinical trials. This review will summarize the advances of HDACi in MNDs and will give a perspective where the road will lead us.
- Published
- 2013
31. Needle Muscle Biopsy
- Author
-
Newman, Eric D. and Garbes, Archimedes D.
- Abstract
We review our experience with needle muscle biopsy, including technique, results, complications, and outcome. We have collected data from 40 consecutive patients undergoing needle muscle biopsy of the quadriceps muscle. All biopsies were performed by the same operator and 98 were performed in the outpatient clinic. Specimens were sent to pathology for processing, staining, and interpretation. Follow-up clinical information was obtained by chart review. The ages of the patients ranged from 9 to 84 years, including three children. Of the 27 patients with a prebiopsy suspicion of idiopathic inflammatory myopathy (polymyositis, dermatomyositis, or inclusion body myositis) 13 had biopsies with consistent pathologic changes. Seven patients in this group had no pathologic diagnosis - none of these patients subsequently developed active myositis. Other conditions seen included mitochondrial myopathy, neuropathy, and type II fiber atrophy. Biopsies were very well tolerated, and no significant complications were seen. Therapeutic decisions were influenced most by needle muscle biopsy results obtained from patients suspected of having idiopathic inflammatory myopathy. Needle muscle biopsy charges were approximately 40 lower than those for open biopsies performed during the same interval. Needle muscle biopsy is a safe, care-effective, and cost-effective alternative to open muscle biopsy in the evaluation of a variety of myopathies.
- Published
- 1997
32. Prospective Assessment of Cholesterol Embolization in Patients With Acute Myocardial Infarction Treated With Thrombolytic vs Conservative Therapy
- Author
-
Blankenship, James C., Butler, Michael, and Garbes, Archimedes
- Abstract
To determine whether subclinical cholesterol embolization is a frequent sequela of thrombolytic therapy. Case reports of catastrophic cholesterol embolization temporally associated with thrombolytic therapy in 19 patients have suggested a causal relationship. Patients and methods: We prospectively followed 60 patients with acute myocardial infarction who underwent coronary bypass surgery within 1 month. Twenty-nine received thrombolytic therapy for myocardial infarction; 31 were treated conservatively. Two muscle biopsy specimens and one skin biopsy specimen were obtained from the vein harvest site at the time of bypass surgery. Paraffin block and frozen sections from each biopsy specimen were analyzed for evidence of cholesterol embolization.
- Published
- 1995
- Full Text
- View/download PDF
33. Hemangioendothelioma of the Hepatobiliary System
- Author
-
Maksimak, Martin, Wilt, Elaine, Colley, A. Thompson, and Garbes, Archimedes
- Abstract
Two children are reported with hemangioen-dothelioma of the hepatobiliary system. One patient, a 7-month-old girl, presented with classic symptomatology of hepatomegaly and congestive heart failure, but did not have any cutaneous lesions. She was treated with systemic steroids and supportive therapy and did very well. The other patient, a 22-month-old boy, is the first patient reported with exclusive involvement of the extrahepatic biliary tree. His symptoms included hepatomegaly and obstructive jaundice. He was evaluated with an endoscopic retrograde cholangiopancreatogram and a transhe-patic cholangiogram. He did very well after resection of the lesion and Roux-en-Y drainage of the proximal biliary tree and remains asymptomatic 2 years after surgery.
- Published
- 1990
34. When the “Blank Slate” Is a White One: White Institutional Isomorphism in the Birth of National Public Radio
- Author
-
Garbes, Laura
- Abstract
A burgeoning literature at the intersection of the sociology of race and organizations explores the organization’s role in (re)producing racial inequalities. The present article builds from this growing literature in its analysis of the formation of National Public Radio (NPR), to better understand how organizational actors translate racialized practices into new organizations at their foundation, even when they seek greater racial inclusivity. I coin a new analytical concept, white institutional isomorphism, to analyze how organizations that embrace a mission of diversity may end up reproducing racially exclusionary practices. White institutional isomorphic pressures are racialized norms that shape the standards and practices adopted across organizations within a given field. Using organizational meeting minutes, external reports, oral histories, and founder memoirs, I show that early implementation of station membership criteria, hiring practices, and programming priorities, while considered race-neutral decisions by the founders that shared a white habitus, inhibited the inclusion of nonwhite voices into NPR’s workforce, station membership, and programming.
- Published
- 2021
- Full Text
- View/download PDF
35. Use of anti-Xa factor titration as efficacy marker of enoxaparin in critically ill patients
- Author
-
Lage, S, Carvalho, R, Kopel, L, Ribeiro, M, Bastos, J, Fagundes Jr, A, Araujo, H, Strunz, C, and Garbes-Netto, P
- Published
- 2006
- Full Text
- View/download PDF
36. GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults.
- Author
-
Palmer CD, Scallan CD, Kraemer Tardif LD, Kachura MA, Rappaport AR, Koralek DO, Uriel A, Gitlin L, Klein J, Davis MJ, Venkatraman H, Hart MG, Jaroslavsky JR, Kounlavouth S, Marrali M, Nganje CN, Bae K, Yan T, Leodones K, Egorova M, Hong SJ, Kuan J, Grappi S, Garbes P, Jooss K, and Ustianowski A
- Subjects
- RNA, Messenger genetics, Humans, Aged, Male, Female, Middle Aged, Aged, 80 and over, Clinical Trials as Topic, Antibodies, Viral immunology, Antibodies, Neutralizing immunology, T-Lymphocytes immunology, COVID-19 prevention & control
- Abstract
SARS-CoV-2 has resulted in high levels of morbidity and mortality world-wide, and severe complications can occur in older populations. Humoral immunity induced by authorized vaccines wanes within 6 months, and frequent boosts may only offer transient protection. GRT-R910 is an investigational self-amplifying mRNA (samRNA)-based SARS-CoV-2 vaccine delivering full-length Spike and selected conserved non-Spike T cell epitopes. This study reports interim analyses for a phase I open-label dose-escalation trial evaluating GRT-R910 in previously vaccinated healthy older adults (NCT05148962). Primary endpoints of safety and tolerability were assessed. Most solicited local and systemic adverse events (AEs) following GRT-R910 dosing were mild to moderate and transient, and no treatment-related serious AEs were observed. The secondary endpoint of immunogenicity was assessed via IgG binding assays, neutralization assays, interferon-gamma ELISpot, and intracellular cytokine staining. Neutralizing antibody titers against ancestral Spike and variants of concern were boosted or induced by GRT-R910 and, contrasting to authorized vaccines, persisted through at least 6 months after the booster dose. GRT-R910 increased and/or broadened functional Spike-specific T cell responses and primed functional T cell responses to conserved non-Spike epitopes. This study is limited due to small sample size, and additional data from ongoing studies will be required to corroborate these interim findings., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
37. AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
- Author
-
Levin MJ, Ustianowski A, Thomas S, Templeton A, Yuan Y, Seegobin S, Houlihan CF, Menendez-Perez I, Pollett S, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Ivanov S, Near KA, Sharbaugh A, Streicher K, Pangalos MN, and Esser MT
- Subjects
- Adult, Humans, SARS-CoV-2, Post-Exposure Prophylaxis, COVID-19 Vaccines, COVID-19 prevention & control
- Abstract
Background: This phase 3 trial assessed AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis against symptomatic coronavirus disease 2019 (COVID-19)., Methods: Adults without prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or COVID-19 vaccination were enrolled within 8 days of exposure to a SARS-CoV-2-infected individual and randomized 2:1 to a single 300-mg AZD7442 dose (one 1.5-mL intramuscular injection each of tixagevimab and cilgavimab) or placebo. Primary end points were safety and first post-dose SARS-CoV-2 reverse-transcription polymerase chain reaction (RT-PCR)-positive symptomatic COVID-19 event before day 183., Results: A total of 1121 participants were randomized and dosed (AZD7442, n = 749; placebo, n = 372). Median (range) follow-up was 49 (5-115) and 48 (20-113) days for AZD7442 and placebo, respectively. Adverse events occurred in 162 of 749 (21.6%) and 111 of 372 (29.8%) participants with AZD7442 and placebo, respectively, mostly mild/moderate. RT-PCR-positive symptomatic COVID-19 occurred in 23 of 749 (3.1%) and 17 of 372 (4.6%) AZD7442- and placebo-treated participants, respectively (relative risk reduction, 33.3%; 95% confidence interval [CI], -25.9 to 64.7; P = .21). In predefined subgroup analyses of 1073 (96%) participants who were SARS-CoV-2 RT-PCR-negative (n = 974, 87%) or missing an RT-PCR result (n = 99, 9%) at baseline, AZD7442 reduced RT-PCR-positive symptomatic COVID-19 by 73.2% (95% CI, 27.1 to 90.1) vs placebo., Conclusions: This study did not meet the primary efficacy end point of post-exposure prevention of symptomatic COVID-19. However, analysis of participants who were SARS-CoV-2 RT-PCR-negative or missing an RT-PCR result at baseline support a role for AZD7442 in preventing symptomatic COVID-19. Clinical Trials Registration. NCT04625972., Competing Interests: Potential conflicts of interest. M. J. L. reports research support from GSK, Johnson & Johnson, Moderna, and Novavax; consultancy for Dynavax, GSK, Merck & Co, Pfizer, and Seqirus; and participation on a data and safety monitoring board (DSMB)/advisory board for GSK. A. U. reports honoraria/speaker fees from Sanofi, Merck, Janssen, GSK, Roche, ViiV, and Gilead; advisory boards for Gilead, Merck, and ViiV/GSK; and participation on a DSMB for COV-Boost study, Flare study, and for Vicore. S. D. P. reports that the USU Infectious Diseases Clinical Research Program (IDCRP), a US Department of Defense institution, and HJF were funded under a cooperative research and development agreement to help conduct the STORM CHASER study, sponsored by AstraZeneca. The HJF, in support of the USU IDCRP, was also funded by the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense to augment the conduct of an unrelated phase 3 vaccine trial sponsored by AstraZeneca. Both of these trials were part of the US government COVID-19 response. M. T. E. reports patents planned, issued, or pending by AstraZeneca on AZD7442. P. G. reports consulting fees from Medicago and Takeda Vaccines as senior medical director; a leadership or fiduciary role as a full member of the Academy of Medicine in Rio de Janeiro, Brazil; and stock or stock options in Takeda Pharmaceuticals, AstraZeneca. All authors report medical writing assistance provided by Prime Global. S. T., A. T., Y. Y., S. S., R. H. A., R. B., K. D., P. G., E. J. K., G. C. K. W. K., S. I., K. A. N., A. S., K. S., M. N. P., and M. T. E. are employees of and hold or may hold stock in AstraZeneca. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2023
- Full Text
- View/download PDF
38. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
- Author
-
Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, Ambery P, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Near KA, Padilla KW, Psachoulia K, Sharbaugh A, Streicher K, Pangalos MN, and Esser MT
- Subjects
- Adult, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal therapeutic use, Antibodies, Neutralizing administration & dosage, Antibodies, Neutralizing therapeutic use, Double-Blind Method, Drug Combinations, Humans, Injections, Intramuscular, SARS-CoV-2, Antiviral Agents administration & dosage, Antiviral Agents therapeutic use, COVID-19 prevention & control
- Abstract
Background: The monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been shown to have prophylactic and therapeutic effects in animal models. Pharmacokinetic data in humans indicate that AZD7442 has an extended half-life of approximately 90 days., Methods: In an ongoing phase 3 trial, we enrolled adults (≥18 years of age) who had an increased risk of an inadequate response to vaccination against coronavirus disease 2019 (Covid-19), an increased risk of exposure to SARS-CoV-2, or both. Participants were randomly assigned in a 2:1 ratio to receive a single dose (two consecutive intramuscular injections, one containing tixagevimab and the other containing cilgavimab) of either 300 mg of AZD7442 or saline placebo, and they were followed for up to 183 days in the primary analysis. The primary safety end point was the incidence of adverse events after a single dose of AZD7442. The primary efficacy end point was symptomatic Covid-19 (SARS-CoV-2 infection confirmed by means of reverse-transcriptase-polymerase-chain-reaction assay) occurring after administration of AZD7442 or placebo and on or before day 183., Results: A total of 5197 participants underwent randomization and received one dose of AZD7442 or placebo (3460 in the AZD7442 group and 1737 in the placebo group). The primary analysis was conducted after 30% of the participants had become aware of their randomized assignment. In total, 1221 of 3461 participants (35.3%) in the AZD7442 group and 593 of 1736 participants (34.2%) in the placebo group reported having at least one adverse event, most of which were mild or moderate in severity. Symptomatic Covid-19 occurred in 8 of 3441 participants (0.2%) in the AZD7442 group and in 17 of 1731 participants (1.0%) in the placebo group (relative risk reduction, 76.7%; 95% confidence interval [CI], 46.0 to 90.0; P<0.001); extended follow-up at a median of 6 months showed a relative risk reduction of 82.8% (95% CI, 65.8 to 91.4). Five cases of severe or critical Covid-19 and two Covid-19-related deaths occurred, all in the placebo group., Conclusions: A single dose of AZD7442 had efficacy for the prevention of Covid-19, without evident safety concerns. (Funded by AstraZeneca and the U.S. government; PROVENT ClinicalTrials.gov number, NCT04625725.)., (Copyright © 2022 Massachusetts Medical Society.)
- Published
- 2022
- Full Text
- View/download PDF
39. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
- Author
-
Sáez-Llorens X, Tricou V, Yu D, Rivera L, Tuboi S, Garbes P, Borkowski A, and Wallace D
- Subjects
- Adolescent, Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology, Asia, Child, Child, Preschool, Dengue Vaccines immunology, Dengue Virus immunology, Double-Blind Method, Humans, Latin America, Safety, Vaccination methods, Vaccines, Attenuated immunology, Dengue prevention & control, Dengue Vaccines therapeutic use, Drug Administration Schedule, Immunogenicity, Vaccine
- Abstract
Background: Dengue is the most common mosquito-borne viral disease in human beings, and vector control has not halted its spread worldwide. A dengue vaccine for individuals aged 9 years and older has been licensed, but there remains urgent medical need for a vaccine that is safe and effective against all four dengue virus serotypes (DENV-1-4) in recipients of all ages. Here, we present the preplanned interim analyses at 6 months of a tetravalent dengue vaccine candidate (TDV), which is comprised of an attenuated DENV-2 virus strain (TDV-2) and three chimeric viruses containing the premembrane and envelope protein genes of DENV-1, DENV-3, and DENV-4 genetically engineered into the attenuated TDV-2 genome backbone (TDV-1, TDV-3, and TDV-4)., Methods: An ongoing phase 2, randomised, double-blind, placebo-controlled trial of a TDV is being done at three sites in dengue-endemic countries (Dominican Republic, Panama, and the Philippines) to determine its safety and immunogenicity over 48 months in healthy participants aged 2-17 years who were randomly assigned (1:2:5:1) using an interactive web response system (stratified by age) to subcutaneous TDV injection (one 0·5 mL dose containing 2·5 × 10
4 plaque-forming units [PFU] of TDV-1; 6·3 × 103 PFU of TDV-2; 3·2 × 104 PFU of TDV-3; and 4·0 × 105 PFU of TDV-4) in different dose schedules (two-dose regimen at 0 and 3 months, one dose at 0 months, or one dose at 0 months and a booster at 12 months) or placebo. The primary endpoint of this 6 month interim analysis was geometric mean titres (GMTs) of neutralising antibodies against DENV-1-4 in the per-protocol immunogenicity subset at 1 month, 3 months, and 6 months after the first injection. Safety was assessed as a secondary outcome as percentage of participants with serious adverse events in all participants who were injected (safety set), and solicited and unsolicited adverse events (immunogenicity subset). This trial is registered with ClinicalTrials.gov, number NCT02302066., Findings: 1800 participants were enrolled between Dec 5, 2014, and Feb 13, 2015. 1794 participants were given study injection as follows: 200 participants were given two-dose regimen at 0 and 3 months (group 1), 398 were given one dose at 0 months (group 2), 998 were given one dose at 0 months and will be given (trial ongoing) a booster at 12 months (group 3), and 198 were given placebo (group 4). These 1794 participants were included in the safety set; 562 participants were randomly assigned to the immunogenicity subset, of which 503 were included in the per-protocol set. TDV elicited neutralising antibodies against all DENV serotypes, which peaked at 1 month and remained elevated above baseline at 6 months. At 6 months, GMTs of neutralising antibodies against DENV-1 were 489 (95% CI 321-746) for group 1, 434 (306-615) for group 2, 532 (384-738) for group 3, and 62 (32-120) for group 4; GMTs of neutralising antibodies against DENV-2 were 1565 (1145-2140) for group 1, 1639 (1286-2088) for group 2, 1288 (1031-1610) for group 3, and 86 (44-169) for group 4; GMTs of neutralising antibodies against DENV-3 were 160 (104-248) for group 1, 151 (106-214) for group 2, 173 (124-240) for group 3, and 40 (23-71) for group 4; and GMTs of neutralising antibodies against DENV-4 were 117 (79-175) for group 1, 110 (80-149) for group 2, 93 (69-125) for group 3, and 24 (15-38) for group 4. No vaccine-related serious adverse events occurred; 15 (3%) of 562 participants in the immunogenicity subset reported vaccine-related unsolicited adverse events. The reactogenicity profile of TDV was acceptable, and similar to previous findings with TDV., Interpretation: TDV is safe and immunogenic in individuals aged 2-17 years, irrespective of previous dengue exposure. A second TDV dose induced enhanced immunogenicity against DENV-3 and DENV-4 in children who were seronegative before vaccination. These data supported the initiation of phase 3 evaluation of the efficacy and safety of TDV given in a two-dose schedule 3 months apart, with analyses that take into account baseline age and dengue serostatus., Funding: Takeda Vaccines., (Copyright © 2017 Elsevier Ltd. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.